Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Galapagos Reports Positive Phase 1 Results for GLPG1205

Published: Wednesday, December 04, 2013
Last Updated: Wednesday, December 04, 2013
Bookmark and Share
Company is developing GLPG1205 within its alliance with Janssen Pharmaceutica NV.

Galapagos NV has announced that GLPG1205, a first-in-class molecule for inflammatory disorders, has demonstrated target engagement, a good safety profile, and favorable drug properties in a Phase 1 study. Galapagos is developing GLPG1205 within its alliance with Janssen Pharmaceutica NV.

The aim of the Phase 1 study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral single and multiple ascending doses of GLPG1205. The randomized, double-blind, placebo-controlled, single center study was conducted in 40 healthy volunteers in Belgium.

In the first part of the study, single ascending doses were evaluated. In the second part, the new compound was administered daily for 14 days.

GLPG1205 was safe and well-tolerated over a wide dose range in healthy volunteers. Engagement of the thus far undisclosed novel target was confirmed using a relevant biomarker.

GLPG1205 displayed a favorable pharmacokinetic and pharmacodynamic profile, potentially supporting once-daily dosing. The data shown in Phase 1 encourage Galapagos to progress GLPG1205 into a Phase 2A study in Inflammatory Bowel Disease (IBD).

"GLPG1205 is the first molecule against this target ever to be evaluated clinically, and we are pleased with the outcome of the Phase 1 study," said Piet Wigerinck, CSO of Galapagos. "Galapagos continues to deliver novel therapeutics from its unique target and drug discovery engine. GLPG1205 will be the fourth compound to enter Phase 2A in our portfolio of proprietary and partnered programs based on novel targets."

In 2007, Galapagos announced an alliance agreement with Janssen Pharmaceutica NV providing the option to worldwide, commercial licenses to certain Galapagos internal inflammatory disease programs.

These programs include a novel target for inflammatory disorders that was identified and validated by Galapagos using its proprietary target discovery engine.

Subsequent Galapagos research led to the discovery of GLPG1205, a first-in-class molecule that entered the clinic for inflammatory disorders. Galapagos is responsible for execution of Phase 1 and Phase 2A studies with GLPG1205.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Thursday, August 25, 2016
Galapagos Starts Phase 1 Study
Company has announced the start of a Phase 1 study with potentiator GLPG2451 for cystic fibrosis (CF).
Tuesday, May 10, 2016
Galapagos, Abbvie Expand Cystic Fibrosis Collaboration
Company has announced that it has expand cystic fibrosis collaboration with Abbvie to reflect the successful expansion of their CF portfolio.
Friday, April 29, 2016
Galapagos Reports Additional Data with Filgotinib
Company has reported 20-week results from its FITZROY study with the investigational, selective JAK1 inhibitor filgotinib in Crohn’s disease.
Saturday, April 23, 2016
Galapagos and MorphoSys initiate Phase 1 study
Company has initiated phase 1 study with MorphoSys AG in joint antibody program MOR106.
Friday, April 08, 2016
Galapagos Initiates a Phase 2a Study with GLPG1690
Company has announced that it has initiated a phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients.
Thursday, April 07, 2016
Galapagos Starts Saphira Phase 2 Study With Glpg1837 In Cystic Fibrosis Patients
Company has announced its Phase 2 exploratory program of GLPG1837 in patients with cystic fibrosis.
Wednesday, February 17, 2016
Galapagos and Gilead Complete Closing of their Global Collaboration for Filgotinib
Triggers an upfront license fee payment of $300 million and equity investment of $425 million.
Thursday, January 21, 2016
Galapagos Advances CF Clinical Development
Initiation of Phase 1 study with corrector GLPG2222, earning Galapagos a $10 million milestone payment from AbbVie.
Wednesday, January 20, 2016
Galapagos Advances Triple Combination Therapy in Cystic Fibrosis
GLPG2665 enters pre-clinical development and completes the first Galapagos-AbbVie triple combination therapy.
Wednesday, October 21, 2015
Positive Safety and Tolerability for Novel Potentiator GLPG1837
Company presents topline Phase 1 results at the North American Cystic Fibrosis Conference in Phoenix.
Saturday, October 10, 2015
Galapagos Presents Promising Pre-clinical and Phase 1 Results
Company presents results for autotaxin inhibitor GLPG1690 at ERS Annual Meeting.
Saturday, September 26, 2015
Galapagos to Advance Filgotinib to Phase 3 in Rheumatoid Arthritis
Phase 3 start in RA expected in early 2016.
Saturday, September 26, 2015
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Tuesday, August 25, 2015
Patient Recruitment Completed in FITZROY Phase 2 Crohn's Disease Study
First selective JAK1 inhibitor in Phase 2 in Crohn's disease.
Friday, August 07, 2015
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Atmosphere Acidity Minimised to Preindustrial Levels
Sheet ice study shows acidic pollution of the atmosphere has now almost returned to preindustrial levels.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Culex Mosquitoes Do Not Transmit Zika
A study of the Culex species mosquito appears to show that the species does not transmit Zika virus.
Uncovering Water Bear Resilience
A protein identified in water bears can protect DNA of human cells from lethal doses of radiation damage.
“Sixth Sense” More Than a Feeling
NIH study of rare genetic disorder reveals importance of touch and body awareness.
Researchers Find Fungus-Fighting Compound
A compound has been identifed that blocks growth of a fungus responsible for lung infections and allergic reactions.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Potential of New Insect Control Traits in Agriculture
Researchers have discovered a protein that shows promise as an alternate corn rootworm control mechanism.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!